================================================================================
MEDICAL VALIDATION REPORT
================================================================================

Total predictions validated: 30
High confidence: 0
Medium confidence: 0
Low confidence: 30

================================================================================
HIGH CONFIDENCE PREDICTIONS (Strong Evidence)
================================================================================

================================================================================
MEDIUM CONFIDENCE PREDICTIONS (Partial Evidence)
================================================================================

================================================================================
LOW CONFIDENCE PREDICTIONS (Weak Evidence)
================================================================================

1. Fexaramine → Myhre syndrome
   Validation Score: 0.4187
   Note: Limited supporting evidence found

2. 16,17-Androstene-3-Ol → congenital hereditary endothelial dystrophy type I
   Validation Score: 0.4173
   Note: Limited supporting evidence found

3. Aminophosphonic acid-guanylate ester → Coats disease
   Validation Score: 0.4161
   Note: Limited supporting evidence found

4. 16,17-Androstene-3-Ol → Meacham syndrome
   Validation Score: 0.4155
   Note: Limited supporting evidence found

5. Fexaramine → X-linked progressive cerebellar ataxia
   Validation Score: 0.4154
   Note: Limited supporting evidence found

================================================================================
END OF REPORT
================================================================================
